Table 2.

Active Randomized Clinical Trials Comparing AHCT versus CAR T Cells

Clinical Trial	Design	Primary Outcome
ZUMA-7 (NCT03391466) Sponsor: Kite, A Gilead Company	Arm A (SOC): Investigator’s choice platinum-based salvage followed by AHCT Arm B (Experimental): Lymphodepleting chemotherapy followed by axicabtagene ciloleucel	Event-free survival
BELINDA (NCT03570892) Sponsor: Novartis	Arm A (SOC): Investigator’s choice platinum-based salvage followed by AHCT Arm B (Experimental): Investigator’s choice of optional platinum-based salvage followed by lymphodepleting chemotherapy followed by tisagenleucel	Event-free survival
TRANSFORM (NCT03575351) Sponsor: Celgene	Arm A (SOC): R-DHAP, R-ICE, or R-GDP followed by AHCT Arm B: Lymphodepleting chemotherapy followed by lisocabtagene maraleucel	Event-free survival

AHCT, autologous hematopoietic cell transplantation; R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin; R-ICE, rituximab, ifosfamide, carboplatin, etoposide; R-GDP, rituximab, gemcitabine, dexamethasone, cisplatin; SOC, standard of care